Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among HIV-positive people, mortality related to hepatitis B and C is falling but deaths due to NAFLD are rising.
At the 24-week mark of a 48-week trial, the treatment showed a trend toward a lack of efficacy.
Patient advocacy groups get together, providing education about this little-known disease.
Nearly a quarter of those taking a higher dose of Ocaliva saw an improvement in liver scarring.
Join the world’s largest meeting of non-alcoholic steatohepatitis stakeholders.
Non-alcoholic fatty liver disease is caused by excess fat in the liver, and can worsen into non-alcoholic steatohepatitis (NASH).
A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.
The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.